Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Hyperpigmentation of the skin and Hypothyroidism; and very common findings: Dry, scaly skin (ichthyosis). 31 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Seizure, Ataxia, Mental deterioration |
Kidneys and urinary system | 5 | Stage 5 chronic kidney disease, Nephrotic syndrome, Steroid-resistant nephrotic syndrome |
Hormones | 3 | Hypogonadism, Hypothyroidism, Adrenal insufficiency |
Eyes | 2 | Strabismus, Ptosis |
Skin | 2 | Hyperpigmentation of the skin, Dry, scaly skin (ichthyosis) |
Muscles | 1 | Generalized hypotonia |
Arms and legs | 1 | Podocyte foot process effacement |
Head and neck | 1 | Microcephaly |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Sphingosine phosphate lyase insufficiency syndrome (SPLIS) is characterized by varying combinations of steroid-resistant nephrotic syndrome, primary adrenal insufficiency (with or without mineralocorticoid deficiency), testicular insufficiency, immunodeficiency, and neurologic abnormalities, and may also include primary hypothyroidism and ichthyosis. To date, 46 individuals with sphingosine phosphate lyase insufficiency syndrome (SPLIS) have been reported [, , , , , , , , , , ]. Of note, the individual reported by is also included in the report by . The following description of the phenotypic features of SPLIS is based on these reports. Table 2. Features of Sphingosine Phosphate Lyase Insufficiency Syndrome
Feature | # of Persons | Comment |
|---|---|---|
Steroid-resistant nephrotic syndrome | 37/46 | — |
Endocrine |
SGPL1 function has not been fully characterized.
Nephrotic syndrome 14 is caused by mutations in the SGPL1 gene on chromosome 10.
Genotype-phenotype correlations are not fully defined for SPLIS. Intrafamilial variability is observed as the clinical manifestations and age of onset can vary within the same family in which affected individuals have the same SGPL1 pathogenic variants. For example, some can be a fetal loss, whereas others develop manifestations in infancy or later in childhood.
Source: GeneReviews — "Sphingosine Phosphate Lyase Insufficiency Syndrome"
Sphingosine phosphate lyase insufficiency syndrome (SPLIS) should be suspected in individuals with any combination of the following clinical, laboratory, and imaging findings and family history.
Clinical findings
Steroid-resistant nephrotic syndrome. Typically congenital or infantile-onset, often associated with focal segmental glomerulosclerosis
• Endocrine
Source: GeneReviews — "Sphingosine Phosphate Lyase Insufficiency Syndrome"
Table 3. Genes of Interest in the Differential Diagnosis of Sphingosine Phosphate Lyase Insufficiency Syndrome
Gene(s) | DiffDx Disorder(s) | MOI | Features of the DiffDx Disorder |
|---|---|---|---|
ALDH3A2 | Sjgren-Larsson syndrome 1 | AR | Ichthyosis; intellectual disability; abnormal brain MRI |
GBA1 (GBA) | Gaucher disease type 2 | AR |
Genetic testing for SGPL1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for nephrotic syndrome 14 has been reported in the published literature.
No approved treatments are currently available for nephrotic syndrome 14. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with sphingosine phosphate lyase insufficiency syndrome (SPLIS), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 5. Recommended Evaluations Following Initial Diagnosis in Individuals with Sphingosine Phosphate Lyase Insufficiency Syndrome
System/Concern | Evaluation | Comment |
|---|---|---|
syndrome | Referral to nephrologist | Serum creatinine/BUN; urine protein/creatinine; renal ultrasound; May require kidney biopsy Primary adrenal |
insufficiency | Endocrinology referral | Early morning ACTH cortisol; Serum electrolytes; Plasma renin activity; Adrenal ultrasound; ACTH stimulation test if baseline results borderline Hypothyroidism |
Immunodeficiency | Consider referral to immunologist. | T-, B-, NK-cell subset analysis; Serum immunoglobulins; T-cell proliferation assays; Antibody titers to vaccinations Poor weight gain/ |
Failure to thrive | Eval by gastroenterology, nutrition, feeding team | Initiation of tube feeding if needed Neurologic |
involvement | Neurologic exam |
Source: GeneReviews — "Sphingosine Phosphate Lyase Insufficiency Syndrome"
Any nephrotoxic drug should be avoided. If renal insufficiency is present, avoid medications that require renal excretion. Live vaccines or exposure to infectious agents may be particularly dangerous due to immunodeficiency. Transfusion products should be irradiated.
Source: GeneReviews — "Sphingosine Phosphate Lyase Insufficiency Syndrome"
Responsiveness to cofactor supplementation (pyridoxine HCl) has been reported in two individuals with sphingosine phosphate lyase insufficiency syndrome . Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Sphingosine Phosphate Lyase Insufficiency Syndrome"
1 trial found
There are no published surveillance guidelines. Based on the known potential medical conditions associated with SPLIS, we propose consideration of the following . Table 7. Recommended Surveillance for Individuals with Sphingosine Phosphate Lyase Insufficiency Syndrome
System/Concern | Evaluation | Frequency |
|---|---|---|
insufficiency | Early morning ACTH, serum cortisol (thereafter ACTH stimulation test if baseline results borderline/abnormal), electrolytes, plasma renin activity | Clinical review analysis every 6-12 mos; in addition, consider before any major procedure. |
Hypothyroidism | Free T4, TSH | Annually Testicular |
insufficiency | Clinical review w/close assessment of pubertal progression, further investigation if delayed onset or poor progression | Annually |
Immunodeficiency | Ongoing eval of lymphocyte count immune function | Every 6-12 mos or more frequent if ongoing infections or other concerns |
Feeding/Nutrition | Monitor growth on age- sex-appropriate curve. | Standard intervals for well-child check-ups; more frequent weight checks if growth rate Neurologic |
involvement | Neurologic exam for new manifestations /or progression | At least annually Musculoskeletal/ |
Mobility/ADL | OT/PT assessment | — |
Hearing | Audiogram | At least annually |
Speech | Speech language pathologist | Development / Educational needs |
Source: GeneReviews — "Sphingosine Phosphate Lyase Insufficiency Syndrome"
Phenotype severity distribution: 2 always present features, 1 very common feature, 5 common features.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
202 publications have been identified in PubMed for nephrotic syndrome 14. Research spans Case Report / Case Series (23%), Epidemiology / Natural History (23%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 38 | 23% |
Disease patterns and progression | 38 | 23% |
Research summaries | 26 | 16% |
Clinical study results | 20 | 12% |
Laboratory research | 17 | 10% |
Testing and diagnosis research | 11 | 7% |
New treatment approaches | 7 | 4% |
Other research | 5 | 3% |
Robinson C (2026). [PMID: 41853741](https://pubmed.ncbi.nlm.nih.gov/41853741/). *Kidney Int Rep*. [Review / Meta-Analysis]
Joshi T (2026). [PMID: 41296007](https://pubmed.ncbi.nlm.nih.gov/41296007/). *Pediatr Nephrol*. [Epidemiology / Natural History]
Annicchiarico Petruzzelli L (2026). [PMID: 41495530](https://pubmed.ncbi.nlm.nih.gov/41495530/). *CEN Case Rep*. [Case Report / Case Series]
Lahme K (2026). [PMID: 41349547](https://pubmed.ncbi.nlm.nih.gov/41349547/). *Cell*. [Basic Science / Preclinical]
Francis J (2026). [PMID: 41615689](https://pubmed.ncbi.nlm.nih.gov/41615689/). *JAMA Netw Open*. [Epidemiology / Natural History]
Hayashi N (2026). [PMID: 41840129](https://pubmed.ncbi.nlm.nih.gov/41840129/). *Sci Rep*. [Case Report / Case Series]
Sophark P (2026). [PMID: 41123654](https://pubmed.ncbi.nlm.nih.gov/41123654/). *Pediatr Nephrol*. [Review / Meta-Analysis]
Dang J (2026). [PMID: 41541779](https://pubmed.ncbi.nlm.nih.gov/41541779/). *Kidney Int Rep*. [Epidemiology / Natural History]
Wu D (2026). [PMID: 41695744](https://pubmed.ncbi.nlm.nih.gov/41695744/). *Front Pediatr*. [Case Report / Case Series]
Zran N (2026). [PMID: 42143272](https://pubmed.ncbi.nlm.nih.gov/42143272/). *BMC Nephrol*. [Case Report / Case Series]
Data assembled from 9 of 12 sources · Last updated Sep 19, 2026, 11:54 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Primary adrenal insufficiency
31/46 |
8/26 w/cryptorchidism /or micropenis Hypothyroidism | 6/46 | — |
Immunodeficiency | 31/46 | — |
Neurologic abnormalities | 22/46 | Cranial nerve deficits (11/46); Strabismus (6/46); Ptosis (2/46); Developmental delay (9/46); Regression/progressive neurologic involvement (6/46); Peripheral motor sensory neuropathy (5/46) |
Spasticity Sensorineural hearing loss | 8/45 | — |
Ichthyosis/acanthosis | 13/46 | 1. , , The range of renal involvement extends from nonimmune fetal hydrops at the severe end to delayed evidence of nephrosis for many years after diagnosis or no renal involvement after years of follow up, as observed in two sibs in their twenties and thirties . |
Source: GeneReviews — "Sphingosine Phosphate Lyase Insufficiency Syndrome"
Ichthyosis; nonimmune hydrops; abnormal brain MRI
LAMB2 | Pierson syndrome (OMIM 609049) | AR | Steroid-resistant nephrotic syndrome; developmental delay |
Lysosomal acid lipase deficiency | AR | Adrenal calcifications | Hepatic fibrosis cirrhosis; intestinal malabsorption LMX1B |
Nail-patella syndrome | AD | Steroid-resistant nephrotic syndrome; sensorineural hearing loss | Nail dysplasia; hypoplastic or absent patellae; eye anomalies NPHS1 NPHS2 |
PLCE1 | Congenital nephrotic syndrome types 1, 2, 3 (OMIM 256300, 600995, 610725) | AR | Steroid-resistant nephrotic syndrome |
Schimke immunoosseous dysplasia | AR | Steroid-resistant nephrotic syndrome; T-cell lymphopenia | Spondyloepiphyseal dysplasia; numerous lentigines AD = autosomal dominant; AR = autosomal recessive; DiffDx = differential diagnosis; MOI = mode of inheritance; SPLIS = sphingosine phosphate lyase insufficiency syndrome 1. Table 4. |
Differential Diagnosis of Clinical Findings Associated with Sphingosine Phosphate Lyase Insufficiency Syndrome Clinical Finding | Distinguishing Features | Comment | — |
Motor/sensory neuropathy | Often autosomal dominant | See Charcot-Marie-Tooth Hereditary Neuropathy Overview. | — |
Congenital ichthyosis | Acanthosis may be observed in SPLIS. | Congenital ichthyosis is a feature of several genetic syndromes.; Nonsyndromic ichthyosis (e.g., autosomal recessive congenital ichthyosis) can be considered if ichthyosis is the presenting finding; syndromic ichthyosis can be assoc w/Netherton syndrome, Sjgren-Larsson syndrome, trichothiodystrophy | — |
Nonimmune hydrops | Enlarged/hemorrhagic adrenals | Many genetic conditions are assoc w/fetal hydrops (e.g., chromosome anomalies, RASopathies, lysosomal storage disorders).1 Primary adrenal insufficiency | Adrenal calcifications, hypothyroidism, cryptorchidism, micropenis may be assoc w/primary adrenal insufficiency. |
Source: GeneReviews — "Sphingosine Phosphate Lyase Insufficiency Syndrome"
Assess for UMN involvement (spasticity, DTRs) LMN involvement (strength, sensation, DTRs); if abnormal consider EMG NCV.; Consider EEG if seizures are a concern.; Brain MRI if not previously performed
Musculoskeletal | Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills; Contractures kyphoscoliosis; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Hearing | Audiologic eval | For sensorineural hearing loss |
Speech | Speech language pathology assessment | For those w/DD /or hearing loss |
Development | Developmental assessment | To incl:; Motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education Ichthyosis/ |
Acanthosis | Dermatology referral if skin abnormalities | Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of SPLIS to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Sphingosine Phosphate Lyase Insufficiency Syndrome Manifestation/Concern | Treatment | Considerations/Other Steroid-resistant nephrotic syndrome |
Primary adrenal insufficiency | By pediatric endocrinologist | Glucocorticoid replacement; Mineralocorticoid replacement as required ± sodium supplementation; Appropriate counseling for sick days; emergency perioperative mgmt Hypothyroidism |
Immunodeficiency | Care by immunologist | Monitor absolute lymphocyte count over time. If proliferation is abnormal, consider avoiding live vaccines. Most affected persons have normal or near-normal T-cell function despite absolute levels. To consider: supportive therapy (e.g., IVIG) to prevent infection based on history lab testing. |
Failure to thrive | Search for underlying etiology, e.g., renal or endocrine problem. | Consider input from nutritionist, parenteral feeding. |
DD/ID | See . | Neurologic |
involvement | Seizure management | Rule out electrolyte disturbances hypoglycemia.; Information is insufficient re specific antiseizure mgmt. |
AI-curated news mentioning nephrotic syndrome 14
Updated Sep 2, 2026
A case report highlights the association of durvalumab with nephrotic syndrome and organizing pneumonia. This finding contributes to the understanding of potential adverse effects linked to durvalumab treatment.
A 17-year clinical course study demonstrates successful management of late-onset nephrotic syndrome in patients with FN1-associated fibronectin glomerulopathy. This research highlights the potential for long-term control of this rare condition.
A study published in PubMed explores the use of sequential anti-CD20 monoclonal antibody and daratumumab in two children with refractory nephrotic syndrome. This research highlights potential therapeutic strategies for a challenging condition.